UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus

Diabetes & metabolism, 2017-12, Vol.43 (6), p.501-511

2017

Volltextzugriff (PDF)

Exenatide: a review from pharmacology to clinical practice

Diabetes, obesity & metabolism, 2009-06, Vol.11 (6), p.544-556

2009

Volltextzugriff (PDF)

Personalized intensification of insulin therapy in type 2 diabetes - does a basal-bolus regimen suit all patients?

Current medical research and opinion, 2016-08, Vol.32 (8), p.1425-1434

2016

Volltextzugriff (PDF)

P308 Impact de l’indice de masse corporelle (IMC ;< 30 kg/m², ≥ 30 – < 35 kg/m², et ≥ 35 kg/m²) initial sur la réponse glycémique et les variations pondérales chez des patients diabétiques de type 2 (DT2) avec un taux initial d’HbA1c ≥ 7,5 % après traitement

Diabetes & metabolism, 2015-03, Vol.41, p.A111-A111

2015

Volltextzugriff (PDF)

Osteoporosis treatment and fracture incidence: the ICARO longitudinal study

Osteoporosis international, 2008-08, Vol.19 (8), p.1219-1223

2008

Volltextzugriff (PDF)

Préférences des patients selon leur âge pour les différentes caractéristiques des agonistes du récepteur du glucagon-like peptide-1 (GLP-1RA) dans le traitement du diabète au Royaume-Uni : un modèle de choix discret

Annales d'endocrinologie, 2016-09, Vol.77 (4), p.504-504

2016

Volltextzugriff (PDF)

Growth Hormone Secretion and Leptin in Morbid Obesity before and after Biliopancreatic Diversion: Relationships with Insulin and Body Composition

The journal of clinical endocrinology and metabolism, 2004-01, Vol.89 (1), p.174-180

2004

Volltextzugriff (PDF)

Profils d’auto-surveillance glycémique des patients diabétiques de type 2 (DT2) traités par dulaglutide (DU) hebdomadaire versus exénatide (EX) en prise bi-quotidienne (BID) et liraglutide (LIR) en prise quotidienne (OD) dans les études AWARD -1 et -6

Annales d'endocrinologie, 2015-09, Vol.76 (4), p.377-377

2015

Volltextzugriff (PDF)

Amélioration de l’HbA1c et du poids selon l’indice de masse corporelle (IMC) initial (< 30, ≥ 30– < 35 et ≥ 35 kg/m2 ) chez des patients diabétiques de type 2 (DT2) à 52 semaines de traitement par dulaglutide (DU) en administration hebdomadaire

Annales d'endocrinologie, 2015-09, Vol.76 (4), p.312-312

2015

Volltextzugriff (PDF)

Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement

Patient preference and adherence, 2018-01, Vol.12, p.707-719

2018

Volltextzugriff (PDF)

Unmet needs among patients with Type 2 diabetes and secondary failure to oral anti-diabetic agents

Journal of endocrinological investigation, 2008-04, Vol.31 (4), p.371-379

2008

Volltextzugriff (PDF)

GH and IGF-I as therapeutic agents for osteoporosis

Journal of endocrinological investigation, 2005, Vol.28 (8 Suppl), p.32-36

2005

Volltextzugriff (PDF)

Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience

Acta diabetologica, 2008-03, Vol.45 (1), p.61-66

2008

Volltextzugriff (PDF)

Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study

Journal of bone and mineral research, 2006-10, Vol.21 (10), p.1565-1570

2006

Volltextzugriff (PDF)

PDB82 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): COUNTRY-SPECIFIC BASELINE CHARACTERISTICS

Value in health, 2019-11, Vol.22, p.S588-S588

2019

Volltextzugriff (PDF)

PDB116 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS

Value in health, 2019-11, Vol.22, p.S593-S593

2019

Volltextzugriff (PDF)

PDB113 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE

Value in health, 2019-11, Vol.22, p.S593-S593

2019

Volltextzugriff (PDF)

PMD177 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH DULAGLUTIDE AND SEMAGLUTIDE INJECTION DEVICES AMONG PATIENTS WITH TYPE 2 DIABETES IN ITALY

Value in health, 2018-10, Vol.21, p.S273-S274

2018

Volltextzugriff (PDF)

PMD105 - Patient Preferences In Italy: Health State Utilities Associated With Attributes Of Weekly Injection Devices For Treatment Of Type 2 Diabetes

Value in health, 2017-10, Vol.20 (9), p.A591-A591

2017

Volltextzugriff (PDF)

Patient Preferences In Italy: Health State Utilities Associated With Attributes Of Weekly Injection Devices For Treatment Of Type 2 Diabetes

Value in health, 2017-10, Vol.20 (9), p.A591

2017

Volltextzugriff (PDF)

Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes

Patient preference and adherence, 2018-01, Vol.12, p.971-979

2018

Volltextzugriff (PDF)

Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: A retrospective evaluation of 50 patients

Metabolism, clinical and experimental, 2002-05, Vol.51 (5), p.616-621

2002

Volltextzugriff (PDF)

Hypothalamic derangement in traumatized patients: growth hormone (GH) and prolactin response to thyrotrophin-releasing hormone and GH-releasing hormone

Clinical endocrinology (Oxford), 1999-06, Vol.50 (6), p.741-747

1999

Volltextzugriff (PDF)

Once-weekly dulaglutide (DU) vs. insulin glargine in the control of fasting serum glucose and hypoglycaemia rate in the first 20 weeks in patients with type 2 diabetes mellitus on metformin and glimepiride

Diabetologie und Stoffwechsel, 2017, Vol.12 (S 01), p.S1-S84

2017

Volltextzugriff (PDF)

Effect of baseline body mass index (BMI; < 30 kg/m2, ≥30-< 35 kg/m2, and ≥35 kg/m2) on glycaemic response and weight change in patients with type 2 diabetes (T2DM) with baseline HbA1c ≥7.5% after treatment with the once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA), dulaglutide, and active comparators in five clinical studies (AWARD 1 – 5)

Diabetologie und Stoffwechsel, 2015, Vol.10 (S 01)

2015

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(35)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(20)
Science & Technology
(19)
Endocrinology & Metabolism
(18)
Life Sciences & Biomedicine
(18)
Female
(12)
Biological And Medical Sciences
(11)
Adult
(10)
Medical Sciences
(9)
Middle Aged
(9)
Male
(7)
Internal Medicine
(6)
Human Growth Hormone - Blood
(5)
Aged
(4)
Endocrinology
(4)
Medicine
(4)
Metabolic Diseases
(4)
Type 2 Diabetes Mellitus
(4)
Biliopancreatic Diversion
(3)
Body Mass Index
(3)
Diabetes Mellitus, Type 2 - Drug Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus

Exenatide: a review from pharmacology to clinical practice

Personalized intensification of insulin therapy in type 2 diabetes - does a basal-bolus regimen suit all patients?

P308 Impact de l’indice de masse corporelle (IMC ;< 30 kg/m², ≥ 30 – < 35 kg/m², et ≥ 35 kg/m²) initial sur la réponse glycémique et les variations pondérales chez des patients diabétiques de type 2 (DT2) avec un taux initial d’HbA1c ≥ 7,5 % après traitement

Osteoporosis treatment and fracture incidence: the ICARO longitudinal study

Préférences des patients selon leur âge pour les différentes caractéristiques des agonistes du récepteur du glucagon-like peptide-1 (GLP-1RA) dans le traitement du diabète au Royaume-Uni : un modèle de choix discret

Growth Hormone Secretion and Leptin in Morbid Obesity before and after Biliopancreatic Diversion: Relationships with Insulin and Body Composition

Profils d’auto-surveillance glycémique des patients diabétiques de type 2 (DT2) traités par dulaglutide (DU) hebdomadaire versus exénatide (EX) en prise bi-quotidienne (BID) et liraglutide (LIR) en prise quotidienne (OD) dans les études AWARD -1 et -6

Amélioration de l’HbA1c et du poids selon l’indice de masse corporelle (IMC) initial (< 30, ≥ 30– < 35 et ≥ 35 kg/m2 ) chez des patients diabétiques de type 2 (DT2) à 52 semaines de traitement par dulaglutide (DU) en administration hebdomadaire

Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement

Unmet needs among patients with Type 2 diabetes and secondary failure to oral anti-diabetic agents

GH and IGF-I as therapeutic agents for osteoporosis

Outcome of pregnancy in type 1 diabetic patients treated with insulin lispro or regular insulin: an Italian experience

Fracture Incidence and Characterization in Patients on Osteoporosis Treatment: The ICARO Study

PDB82 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): COUNTRY-SPECIFIC BASELINE CHARACTERISTICS

PDB116 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS

PDB113 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE

PMD177 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH DULAGLUTIDE AND SEMAGLUTIDE INJECTION DEVICES AMONG PATIENTS WITH TYPE 2 DIABETES IN ITALY

PMD105 - Patient Preferences In Italy: Health State Utilities Associated With Attributes Of Weekly Injection Devices For Treatment Of Type 2 Diabetes

Patient Preferences In Italy: Health State Utilities Associated With Attributes Of Weekly Injection Devices For Treatment Of Type 2 Diabetes

Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes

Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: A retrospective evaluation of 50 patients

Hypothalamic derangement in traumatized patients: growth hormone (GH) and prolactin response to thyrotrophin-releasing hormone and GH-releasing hormone

Once-weekly dulaglutide (DU) vs. insulin glargine in the control of fasting serum glucose and hypoglycaemia rate in the first 20 weeks in patients with type 2 diabetes mellitus on metformin and glimepiride

Suchergebnisse filtern